J Gu1, M Delisle2, R Engler-Stringer1, G Groot1. 1. Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK. 2. Department of Surgery, University of Manitoba, Winnipeg, MB.
Abstract
Background: The choice of mastectomy compared with breast-conservation therapy (bct) in early-stage breast cancer (esbca) is a complicated decision-making process. Interprovincially, Canada's mastectomy rates vary from 25% to 68%, with Saskatchewan reporting the nation's second-highest mastectomy rate at 63%. The aim of our research was to better understand why women with esbca choose mastectomy rather than bct in Saskatchewan. Methods: We created a survey based on a previously developed framework that organizes influencing factors into 3 constructs: clinicopathologic, physician, and individual belief factors. Results: Treatment choice was found to be influenced by disease stage and multiple individual belief factors. Compared with their counterparts having stage i disease, women with stage ii disease were significantly more likely to undergo mastectomy [odds ratio (or): 7.48]. Patients rating "worry about cancer recurrence" and "total treatment time" as more influential in their choice were also more likely to undergo mastectomy (or: 3.4 and 1.8 respectively). Conversely, women rating "wanting to keep own breast tissue," "tumour size," and "surgeon's opinion" as influential in their choice were more likely to undergo bct (or: 0.17, 0.66, and 0.69 respectively). Conclusions: Our study demonstrates that treatment choices for Saskatchewan women with esbca are influenced primarily by disease stage and individual belief factors. Those findings suggest that women are making their treatment choices predominantly based on individual values and preferences. The use of rates of mastectomy and bct as indicators of quality of care might be misleading. Instead, a shift in attention toward patient-centred care might be more appropriate.
Background: The choice of mastectomy compared with breast-conservation therapy (bct) in early-stage breast cancer (esbca) is a complicated decision-making process. Interprovincially, Canada's mastectomy rates vary from 25% to 68%, with Saskatchewan reporting the nation's second-highest mastectomy rate at 63%. The aim of our research was to better understand why women with esbca choose mastectomy rather than bct in Saskatchewan. Methods: We created a survey based on a previously developed framework that organizes influencing factors into 3 constructs: clinicopathologic, physician, and individual belief factors. Results: Treatment choice was found to be influenced by disease stage and multiple individual belief factors. Compared with their counterparts having stage i disease, women with stage ii disease were significantly more likely to undergo mastectomy [odds ratio (or): 7.48]. Patients rating "worry about cancer recurrence" and "total treatment time" as more influential in their choice were also more likely to undergo mastectomy (or: 3.4 and 1.8 respectively). Conversely, women rating "wanting to keep own breast tissue," "tumour size," and "surgeon's opinion" as influential in their choice were more likely to undergo bct (or: 0.17, 0.66, and 0.69 respectively). Conclusions: Our study demonstrates that treatment choices for Saskatchewan women with esbca are influenced primarily by disease stage and individual belief factors. Those findings suggest that women are making their treatment choices predominantly based on individual values and preferences. The use of rates of mastectomy and bct as indicators of quality of care might be misleading. Instead, a shift in attention toward patient-centred care might be more appropriate.
Authors: Sabine Stordeur; France Vrijens; Stephan Devriese; Koen Beirens; Elizabeth Van Eycken; Joan Vlayen Journal: Breast Date: 2011-11-06 Impact factor: 4.380
Authors: M Rosselli Del Turco; A Ponti; U Bick; L Biganzoli; G Cserni; B Cutuli; T Decker; M Dietel; O Gentilini; T Kuehn; M P Mano; P Mantellini; L Marotti; P Poortmans; F Rank; H Roe; E Scaffidi; J A van der Hage; G Viale; C Wells; M Welnicka-Jaskiewicz; Y Wengstöm; L Cataliotti Journal: Eur J Cancer Date: 2010-07-31 Impact factor: 9.162
Authors: Nadeem Q Mirza; Georges Vlastos; Funda Meric; Thomas A Buchholz; Nestor Esnaola; S Eva Singletary; Henry M Kuerer; Lisa A Newman; Frederick C Ames; Merrick I Ross; Barry W Feig; Raphael E Pollock; Marsha McNeese; Eric Strom; Kelly K Hunt Journal: Ann Surg Oncol Date: 2002-04 Impact factor: 5.344
Authors: Walley J Temple; Margaret L Russell; Louise L Parsons; Sylvia M Huber; Charlotte A Jones; Jane Bankes; Michael Eliasziw Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Roland Reitsamer; Christian Menzel; Sylvia Glueck; Wolfgang Hitzl; Florentia Peintinger Journal: Breast J Date: 2008 Jul-Aug Impact factor: 2.431
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Soudabeh Fazeli; Bradley S Snyder; Ilana F Gareen; Constance D Lehman; Seema A Khan; Justin Romanoff; Constantine A Gatsonis; Ralph L Corsetti; Habib Rahbar; Derrick W Spell; Kenneth B Blankstein; Linda K Han; Jennifer L Sabol; John R Bumberry; Kathy D Miller; Joseph A Sparano; Christopher E Comstock; Lynne I Wagner; Ruth C Carlos Journal: JAMA Netw Open Date: 2022-05-02